FDA agrees to X4's reduced 4WARD trial sample size (176 to 126); topline data expected H1 2028

X4 Pharmaceuticals, Inc

FDA agreed to cut 4WARD Phase 3 sample size from 176 to 126 patients, preserving power for co-primary endpoints.
Safety database deemed acceptable to support potential sNDA for mavorixafor in chronic neutropenia.
Enrollment of 4WARD expected to complete by end of 2026; topline data in H1 2028.
Mavorixafor targets ~15,000 patients with serious/recurring infections due to chronic neutropenia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.